Bausch Health Companies Inc. (NYSE:BHC) is Biglari Capital CORP.'s 8th Largest Position

Biglari Capital CORP. lowered its holdings in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 25.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 295,000 shares of the company's stock after selling 100,000 shares during the quarter. Bausch Health Companies comprises approximately 0.3% of Biglari Capital CORP.'s investment portfolio, making the stock its 8th largest holding. Biglari Capital CORP. owned about 0.08% of Bausch Health Companies worth $2,378,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Bausch Health Companies by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company's stock worth $94,460,000 after acquiring an additional 145,078 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Bausch Health Companies by 1.1% during the 4th quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company's stock valued at $42,855,000 after acquiring an additional 56,446 shares during the period. Maple Rock Capital Partners Inc. increased its position in shares of Bausch Health Companies by 156.7% in the fourth quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock valued at $42,718,000 after acquiring an additional 3,235,100 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Bausch Health Companies by 46.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock worth $38,501,000 after acquiring an additional 1,510,445 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of Bausch Health Companies by 62.0% in the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock valued at $26,614,000 after purchasing an additional 1,263,706 shares during the period. Institutional investors own 78.65% of the company's stock.

Analyst Upgrades and Downgrades

BHC has been the subject of several recent analyst reports. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada lifted their price objective on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd. Finally, StockNews.com raised Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $7.42.

Bausch Health Companies Stock Performance

Shares of NYSE:BHC traded down $0.13 during trading on Friday, hitting $4.57. The company's stock had a trading volume of 895,742 shares, compared to its average volume of 2,644,802. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $9.85. The business has a 50 day moving average price of $5.84 and a two-hundred day moving average price of $7.13. The company has a market capitalization of $1.65 billion, a PE ratio of -38.08, a P/E/G ratio of 0.37 and a beta of 0.34.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The company had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. As a group, equities analysts expect that Bausch Health Companies Inc. will post 4.41 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.